The main goal of this work was to examine the systemic levels of IL-13 in patients with insulin resistance, while also studying the relationship of IL-13 with parameters of low-grade systemic inflammation such as TNF-α, IL-10, Mon-CD11c+CD206− percentage, and Mon-CD11c−CD206+ percentage, and other insulin resistance-related metabolic markers including fasting blood glucose and insulin, BMI, central obesity, body fat percentage, waist-to-hip ratio, triglycerides, and cholesterol. Here, ITGAX is linked to Insulin resistance.